Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 2/20 | 1.00 |
| ▸ | PDE4B known ✓ | Q07343 | 2/20 | 1.00 |
| ▸ | PDE4C known ✓ | Q08493 | 2/20 | 1.00 |
| ▸ | PDE4D known ✓ | Q08499 | 2/20 | 1.00 |
| ▸ | PDE5A | O76074 | 6/20 | 1.00 |
| ▸ | PDE2A | O00408 | 1/20 | 1.00 |
| ▸ | PDE1A | P54750 | 1/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 1/20 | 1.00 |
| ▸ | PDE1C | Q14123 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 10/20 | 0.51 |
| ▸ | HTR3A | P46098 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HRH1 | P35367 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL7504145 | 0.98 | PDE5A (0.97) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL149748 | 0.92 | PDE4A (1.00) | PDE5APDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL29801523 | 0.92 | PDE4A (0.98) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5917668 | 0.92 | PDE4A (0.98) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7504141 | 0.92 | PDE4A (0.98) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5917665 | 0.92 | PDE4A (0.98) | PDE5APDE4APDE4BPDE4CPDE4D | |
| Potassium SCHEMBL7504150 | 0.92 | PDE4A (0.98) | PDE5APDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL7502602 | 0.92 | PDE4A (0.98) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7500079 | 0.91 | PDE4A (0.87) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7502434 | 0.89 | PDE4A (0.92) | PDE5APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387433-A1 | TYPE V PHOSPHODIESTERASE INHIBITOR COMPOSITIONS, METHODS OF MAKING THEM AND METHODS OF USING THEM IN PREVENTING OR TREATING ELEVATED PULMONARY VASCULAR PRESSURE OR PULMONARY HEMORRHAGES | AMERICAN REGENT, INC. (US) | 2022-12-08 | — | — | US | claimed |
| EP-4058026-A2 | TYPE V PHOSPHODIESTERASE INHIBITOR COMPOSITIONS, METHODS OF MAKING THEM AND METHODS OF USING THEM | American Regent, Inc. (US) | 2022-09-21 | — | — | EP | claimed |
| CN-114929233-A | Phosphodiesterase type V inhibitor compositions, methods of making them, and methods of using them | 美国瑞根特有限公司 | 2022-08-19 | — | — | CN | claimed |
| WO-2021096871-A2 | TYPE V PHOSPHODIESTERASE INHIBITOR COMPOSITIONS, METHODS OF MAKING THEM AND METHODS OF USING THEM IN PREVENTING OR TREATING ELEVATED PULMONARY VASCULAR PRESSURE OR PULMONARY HEMORRHAGES | AMERICAN REGENT, INC. (US) | 2021-05-20 | — | — | WO | claimed |
| EP-0754069-B1 | TREATMENT OF PULMONARY VASOCONSTRICTION AND ASTHMA | GEN HOSPITAL CORP (US) | 2004-06-23 | — | — | EP | claimed |
| EP-1418896-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | Vivus, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| WO-2003000343-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | VIVUS, INC. (US) | 2003-01-03 | — | — | WO | claimed |
| US-6403597-B1 | PRETREATMENT SEXUAL INTERCOURSE | VIVUS, INC. | 2002-06-11 | — | — | US | claimed |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | VIVUS, INC. | 2002-03-28 | — | — | US | claimed |
| JP-9059159-A | — | — | None | — | — | JP | disclosed |
| US-20220387433-A1 | TYPE V PHOSPHODIESTERASE INHIBITOR COMPOSITIONS, METHODS OF MAKING THEM AND METHODS OF USING THEM IN PREVENTING OR TREATING ELEVATED PULMONARY VASCULAR PRESSURE OR PULMONARY HEMORRHAGES | AMERICAN REGENT, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220387433-A1 | TYPE V PHOSPHODIESTERASE INHIBITOR COMPOSITIONS, METHODS OF MAKING THEM AND METHODS OF USING THEM IN PREVENTING OR TREATING ELEVATED PULMONARY VASCULAR PRESSURE OR PULMONARY HEMORRHAGES | AMERICAN REGENT, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| EP-4058026-A2 | TYPE V PHOSPHODIESTERASE INHIBITOR COMPOSITIONS, METHODS OF MAKING THEM AND METHODS OF USING THEM | American Regent, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| EP-4058026-A2 | TYPE V PHOSPHODIESTERASE INHIBITOR COMPOSITIONS, METHODS OF MAKING THEM AND METHODS OF USING THEM | American Regent, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| US-6262059-B1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | CELL PATHWAYS, INC. | 2001-07-17 | — | — | US | disclosed |
| US-5801180-A | ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | EISAI CO., LTD. (JP) | 1998-09-01 | — | — | US | disclosed |
| US-5693652-A | Benzimidazoles for ischemic heart conditions | EISAI CO., LTD. (JP) | 1997-12-02 | — | — | US | disclosed |
| JP-H0959159-A | MEDICINAL COMPOSITION IMPROVED IN ABSORPTION | EISAI CO LTD | 1997-03-04 | — | — | JP | disclosed |
| US-5576322-A | Anti-ischemic 2,4-diaminoquinazolines | EISAI CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0607439-A1 | NITROGENOUS HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 1994-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | PDE5A, PDE3B, PDE3A | PDE4A 5/4885PDE4B 8/4885PDE4C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.